{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:34:47Z","timestamp":1794674087109,"version":"4.9.1"},"reference-count":81,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Eye Institute - U.S.","id":[{"id":"https:\/\/ror.org\/03wkg3b53","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R24\/EY032440"],"award-info":[{"award-number":["R24\/EY032440"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T35\/HL120835"],"award-info":[{"award-number":["T35\/HL120835"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dr. John P. and Therese E. Mulcahy Endowed Professorship in Ophthalmology"},{"DOI":"10.13039\/100017982","name":"Illinois Society for the Prevention of Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Cutaneous and Ocular Toxicology"],"published-print":{"date-parts":[[2025,10,2]]},"DOI":"10.1080\/15569527.2025.2573463","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:36:58Z","timestamp":1761554218000},"page":"361-373","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Clinical and pharmacovigilance safety evaluation of LUXTURNA\n                    <sup>\u00ae<\/sup>\n                    (voretigene neparvovec-rzyl)"],"prefix":"10.1080","volume":"44","author":[{"given":"Djamilla","family":"Simoens","sequence":"first","affiliation":[{"name":"Program in Pharmacovigilance, Loyola University Chicago, Health Sciences Campus","place":["Maywood, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Shravah","sequence":"additional","affiliation":[{"name":"Stritch School of Medicine, Loyola University Chicago, Health Sciences Campus","place":["Maywood, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Keith","family":"Jones","sequence":"additional","affiliation":[{"name":"Program in Pharmacovigilance, Loyola University Chicago, Health Sciences Campus","place":["Maywood, USA"]},{"name":"Department of Pharmacology and Neuroscience, Loyola University Chicago, Health Sciences Campus","place":["Maywood, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kaja","sequence":"additional","affiliation":[{"name":"Program in Pharmacovigilance, Loyola University Chicago, Health Sciences Campus","place":["Maywood, USA"]},{"name":"Department of Pharmacology and Neuroscience, Loyola University Chicago, Health Sciences Campus","place":["Maywood, USA"]},{"name":"Department of Ophthalmology, Loyola University Chicago, Health Sciences Campus, Health Sciences Campus","place":["Maywood, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-02036-7"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1913179117"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13917"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137207"},{"key":"e_1_3_3_6_1","first-page":"626","article-title":"The clinical features of retinal disease due to a dominant mutation in RPE65","volume":"22","author":"Hull S","year":"2016","unstructured":"Hull S, Mukherjee R, Holder GE, et al. The clinical features of retinal disease due to a dominant mutation in RPE65. Mol Vis. 2016;22:626\u2013635.","journal-title":"Mol Vis"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.029"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.09.004"},{"key":"e_1_3_3_9_1","volume-title":"LUXTURNA (voretigene neparvovec-rzyl) prescribing information","author":"(FDA) USFaDA","year":"2017","unstructured":"(FDA) USFaDA. LUXTURNA (voretigene neparvovec-rzyl) prescribing information. Silver Spring, MD: Center for Biologics Evaluation and Research (CBER); 2017."},{"key":"e_1_3_3_10_1","unstructured":"FDA. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss; 2017. [cited 2025 July 15] https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss."},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2024.252"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/300611a0"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5235.475"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/343364a0"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(90)90223-h"},{"key":"e_1_3_3_16_1","unstructured":"Miller CG Bennett J Maguire AM et al. Development of Luxturna gene therapy; 2022 [cited 2025 July 15]. https:\/\/retinahistory.asrs.org\/milestones-developments\/the-history-and-development-of-luxturna-gene-therapy."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051450"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.21.7413"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.18.6982"},{"issue":"5","key":"e_1_3_3_20_1","first-page":"2535","article-title":"Adenovirus vector-mediated in vivo gene transfer into adult murine retina","volume":"35","author":"Bennett J","year":"1994","unstructured":"Bennett J, Wilson J, Sun D, et al. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci. 1994;35(5):2535\u20132542.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"e_1_3_3_21_1","first-page":"2543","article-title":"In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector","volume":"35","author":"Li T","year":"1994","unstructured":"Li T, Adamian M, Roof DJ, et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci. 1994;35(5):2543\u20132549.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-649"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.17.9920"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0076-6879(00)16762-x"},{"issue":"13","key":"e_1_3_3_25_1","first-page":"2857","article-title":"Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction","volume":"38","author":"Bennett J","year":"1997","unstructured":"Bennett J, Duan D, Engelhardt JF, et al. Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest Ophthalmol Vis Sci. 1997;38(13):2857\u20132863.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"e_1_3_3_26_1","first-page":"2211","article-title":"In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells","volume":"36","author":"Budenz DL","year":"1995","unstructured":"Budenz DL, Bennett J, Alonso L, et al. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1995;36(11):2211\u20132215.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0525"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0501-92"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1999.5754"},{"key":"e_1_3_3_30_1","first-page":"23","article-title":"Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect","volume":"4","author":"Aguirre GD","year":"1998","unstructured":"Aguirre GD, Baldwin V, Pearce-Kelling S, et al. Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect. Mol Vis. 1998;4:23.","journal-title":"Mol Vis"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.08.008"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300389"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802315"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802268"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.107"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61836-5"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002865"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30371-3"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"e_1_3_3_40_1","unstructured":"U.S. Food and Drug Administration (FDA). BLA Approval Letter \u2013 Voretigene Neparvovec-rzyl (Luxturna\u00ae). Silver Spring MD: U.S. Food and Drug Administration; December 19 2017. Available from: https:\/\/www.fda.gov\/media\/109906\/download"},{"key":"e_1_3_3_41_1","unstructured":"European Medicines Agency (EMA). Orphan Maintenance Assessment Report: Luxturna (voretigene neparvovec). Initial authorisation. London UK: European Medicines Agency; 2018.Available from: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/luxturna-orphan-maintenance-assessment-report-initial-authorisation_en.pdf"},{"key":"e_1_3_3_42_1","unstructured":"Gazette S. SFDA okays first genetic drug to treat poor sight. 2019. [cited 2025 July 15] https:\/\/saudigazette.com.sa\/article\/579207"},{"key":"e_1_3_3_43_1","unstructured":"Retina International. The future is bright: Health Canada approves first sight-restoring gene therapy for inherited eye diseases. 2020. [cited 2025 July 15]. https:\/\/retina-international.org\/luxturna-is-first-ever-gene-therapy-to-be-approved-in-canada\/"},{"key":"e_1_3_3_44_1","unstructured":"Casimir Jones SC. First gene therapy products approved in Brazil: Lexology; 2020. https:\/\/www.lexology.com\/library\/detail.aspx?g=5347d335-423c-4bb8-8746-187e126c8de8#:\u223c:text=Brazil%20has%20become%20the%20first Luxturna\u00ae%20and%20Zolgensma\u00ae."},{"key":"e_1_3_3_45_1","unstructured":"Health TGATAGDo. Luxturna approval; 2020."},{"key":"e_1_3_3_46_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Approval of Luxturna (voretigene neparvovec). Tokyo Japan: Pharmaceuticals and Medical Devices Agency; 2023. Available from: https:\/\/www.pmda.go.jp\/files\/000266878.pdf"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.101013"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/13816810802626399"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M105423200"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050785"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.03.031"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.03.016"},{"key":"e_1_3_3_53_1","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approval Letter: STN BL 125610\/293 \u2013 Supplement for Voretigene Neparvovec-rzyl (Luxturna): Addition of Chorioretinal Atrophy to Prescribing Information. Silver Spring MD: U.S. Food and Drug Administration; 2022. Available from: https:\/\/www.fda.gov\/media\/159107\/download"},{"key":"e_1_3_3_54_1","unstructured":"EMA. Luxturna (voretigene neparvovec)\u2014EPAR product details. European Medicine Agency (EMA); 2018 [cited 2018 Sept 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/luxturna#authorisation-details"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.015"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03691-8"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.08.017"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2038"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.2.13"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.09.006"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.6.11"},{"key":"e_1_3_3_62_1","unstructured":"Simoens D. FAERS PHARMACOVIGILANCE ANALYSIS - Custom Python Pipeline for FAERS Pharmacovigilance Analysis: GitHub; 2025. https:\/\/github.com\/DSimoens\/FAERS_PHARMACOVIGILANCE_ANALYSIS"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2024.12.006"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03637-0"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-326221"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1515\/medgen-2025-2012"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03672-x"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010122"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.05.005"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2018.168"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.11.021"},{"key":"e_1_3_3_72_1","unstructured":"Wakefield J. Bionic eyes: Obsolete tech leaves patients in the dark. BBC News; 2022 [cited 2022 Feb 17]. https:\/\/www.bbc.com\/news\/technology-60416058."},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-092818-015530"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.01.019"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0218-122"},{"key":"e_1_3_3_76_1","unstructured":"Spark Therapeutics Inc. Spark therapeutics announces first-of-their-kind programs to improve patient access to LUXTURNA\u2122 (voretigene neparvovec-rzyl) a one-time gene therapy treatment; 2018. https:\/\/www.globenewswire.com\/news-release\/2018\/01\/03\/1281548\/0\/en\/Spark-Therapeutics-Announces-First-of-their-kind-Programs-to-Improve-Patient-Access-to-LUXTURNA-voretigene-neparvovec-rzyl-a-One-time-Gene-Therapy-Treatment.html"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00419-9"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0118"},{"key":"e_1_3_3_79_1","unstructured":"Spark Therapeutics Inc. LUXTURNA\u00ae ocular gene therapy treatment centers; 2025. https:\/\/luxturnahcp.com\/about-luxturna\/treatment-centers\/."},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00862-2"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13185512"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101426"}],"container-title":["Cutaneous and Ocular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15569527.2025.2573463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:50:34Z","timestamp":1763574634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15569527.2025.2573463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10,2]]}},"alternative-id":["10.1080\/15569527.2025.2573463"],"URL":"https:\/\/doi.org\/10.1080\/15569527.2025.2573463","relation":{},"ISSN":["1556-9527","1556-9535"],"issn-type":[{"value":"1556-9527","type":"print"},{"value":"1556-9535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icot20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icot20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}